NCT05116540View on ClinicalTrials.gov

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 24, 2021

Primary Completion Date

June 4, 2024

Study Completion Date

June 4, 2024

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL

HB-adMSCs

Autologous product

DRUG

Placebo

Normal Saline

Trial Locations (1)

77478

Hope Biosciences Stem Cell Research Foundation, Sugar Land

All Listed Sponsors

lead

Hope Biosciences Research Foundation

INDUSTRY

NCT05116540 - Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis | Biotech Hunter | Biotech Hunter